Unmet Need:
According to the WHO, approximately 4.9 million people globally are affected by bacteria that leads to corneal scarring of the eye (WHO). Additionally, in the United States alone 4.88 million people age 50 and older suffer from dry eye, which may lead to scarring of the cornea (Healthline). The cornea serves as a window to the eye, and transparency is central to its function. The cornea is comprised of uniquely organized extracellular matrix biomaterials that provide tissue transparency and allow for vision. However, when this highly organized matrix structure is damaged, fibrotic scar tissue develops that leads to corneal opacity and vision obstruction. Conventional eye drops that are used to stop inflammation and prevent scar formation within the eye involve steroid compounds. However, these treatments can have significant limitations in that they may lead to corneal melting or glaucoma. Therefore, there is an unmet need for efficacious therapeutic options to treat traumatic injuries from physical and chemical abrasions, as well as cornea damage associated with the rising number of elective cornea surgical procedures.
Technology Overview:
Johns Hopkins researchers have developed a therapeutic modality whereby a pro-regenerative biomaterial can harness immune cells to promote a scar-less repair of the eye. This invention deploys a concept of regenerative immunotherapies by use of a biomaterial that is capable of targeting the immunological pathways, during ocular surface wound healing and inflammatory disease, for cornea repair. This therapy may easily be integrated into an eye-drop product or remain in liquid form for more advanced injection procedures.
Stage of Development:
Pre-clinical murine data is available.
Publications:
N/A
